Affluent Partners (HKG:1466) unit Beijing Baijin Biotechnology entered into a strategic cooperation framework agreement with Taihe Huamei (Zhejiang) Medical Technology to develop a new medicine in Mainland China, a Monday bourse filing said.
The new medicine, KMHH-03, which has been developed by Taihe Huamei (Zhejiang) Medical Technology, has obtained preliminary approval from China's National Medical Products Administration and is currently undergoing first-stage clinical research.
Under the contract, Beijing Baijin Biotechnology will invest in Taihe Huamei (Zhejiang) Medical Technology by subscribing for equity interest in the latter.
The parties are yet to decide the time and value of the investment under the contract, which will expire Dec. 31, 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.